Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from H.E. Fjosne and co-authors provides new data about breast cancer
March 20th, 2008
In this recently published article, scientists in Trondheim, Norway conducted a study "To evaluate possible differences in effect on recurrence-free survival (RFS) and overall survival (OS) in node positive postmenopausal breast cancer patients receiving Tamoxifen or cyclic Tam and Megestrol acetate as adjuvant treatment. Between 1989 and 1994, 489 patients with pT(1) -(2)pN+ hormone receptor positive or unknown tumours were included in a randomized national multicenter study to receive either Tam alone or cyclic Tam (8 weeks) and MA (8 weeks) for 2 years." "Final follow-up was completed as of June 2002. Time from start of treatment to first recurrence and novel...
Source: Women's Health Weekly (2008-03-20)
|
